Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
argenx SE enters its October 22 quarterly results down 14% on the week and nearly 16% over the past month, a sharp deterioration that makes the insider selling flagged last week look increasingly well-timed.
The stock closed at EUR 718.60 on October 13, down from levels above EUR 900 when the CEO and other senior executives sold in early September. Founder and CEO Timothy Van Hauwermeiren disposed of 20,000 shares at EUR 908 on September 3, a EUR 18.2 million transaction. The General Counsel and Chief Medical Officer added further sales totalling around EUR 2.7 million in the same period. The net insider position over 90 days amounts to 32,589 shares sold, worth roughly EUR 47.7 million. None were flagged as pre-arranged plan trades. Those sellers, who acted at prices 20% to 26% above where the stock trades today, now look prescient rather than merely cautious.
The lending market has not reacted to the selloff as a short opportunity. Borrow availability remains extraordinarily loose at 4,429%, meaning far more shares are available to lend than are currently borrowed. Borrowing costs are running at just 0.67%, practically unchanged over the week, and the ORTEX short score of 31.4 places argenx in a relatively unbothered part of the universe. The valuation re-rating is happening through forced sellers or disappointed longs, not through a build in short conviction. Peers had a rough week too: VRTX fell 3.4% and BSLN dropped 1.7%, suggesting some sector-wide pressure, though argenx's loss is considerably deeper than either.
What has shifted since the previous note is the valuation context. The price-to-earnings multiple has compressed to around 22.4x, down more than 6 points over 30 days, and price-to-book has fallen to 4.2x over the same period. EV/EBITDA now sits at 18.5x, off 2.7 points in a month. The analyst data in the snapshot is stale and cannot be quoted as current. On factor scores, argenx ranks in the 92nd percentile for 30-day EPS momentum and 86th for 90-day EPS momentum, meaning the fundamental estimate trend has not deteriorated nearly as much as the share price. That gap between falling price and resilient earnings momentum is the central tension heading into the print.
The alt data for argenx covers drug trials tracked by the US National Library of Medicine. The dataset has no measured or tested relationship to the company's reported figures, so it adds colour on pipeline activity but is not a leading indicator for the October 22 release.
With eight days to the next quarterly report and the stock having shed 16% in the past month, the earnings print will either validate or challenge the logic of the insider sales made six weeks ago at prices a fifth higher than today's close.
See the live data behind this article on ORTEX.
Open ARGX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
